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Clinical Applications of a Combination Therapy using 8-Cl cAMP and 8-Cl Adenosine
Erik Munoz, Andrea Saich, Andrew Cox and Dr. Yu-An (Peter) Chang

Introduction

Discussion

Dr. Cho-Chung from NIH first thought to use halogenated cAMP derivatives as competitive inhibitors of
cAMP to slow down cancer cell mitosis (1). Experimental results indicated that 8-Iodo cAMP did not
have any biological activity, while 8-Bromo cAMP showed minimum inhibition, and 8-Chloro cAMP (8-ClcAMP) provided significant anti-cancer activity.
8-Cl cAMP was found to be a broad spectrum anti-cancer drug against many cancer cells in vitro - such
as in leukemia, breast cancer, lung cancer, etc. This molecule helped to slow down cancer cell growth
giving time for the cancer cells to respond to signals from surrounding normal cells. This gave white
blood cells sufficient time to recognize and eliminate the cancerous cells. Additionally, some of the
cancer cells were observed reverting back to normal cells morphologically.
With its many positive results, 8-Cl cAMP entered Phase II clinical trials. However, the phosphate group
on the 8-Cl cAMP made it very water soluble; consequently, it quickly flushed out of the patients’ body, as
do hydrophilic vitamins such as Vitamin C. Peristaltic pumps were thus employed to pump the 8-Cl
cAMP into patients’ veins continuously to maintain drug concentrations. Although 8-Cl-cAMP had very
low human toxicity, high exposures to this drug resulted in side effects that prevented it from reaching
Phase III clinical trials.
Since Adenosine can be converted to cAMP in vivo through the human biological pathway naturally, 8-Cl
cAMP therefore can also be converted from 8-Cl-Adenosine through the same biological pathway. This
has been confirmed by many published studies. Thus 8 Cl-Adenosine can serve as a pro-drug for 8-ClcAMP to provide a constant concentration of 8-Cl-cAMP in the cancer patient blood plasma. This can
also reduce the dosage necessary for treatment. The combination therapy using 8-Cl cAMP and 8-Cl
Adenosine (as a pro-drug of 8-Cl cAMP) will certainly provide the optimum clinical outcomes for cancer
patients.

Cyclic adenosine mono phosphate (cAMP) is a major component of various pathways which
regulate cell growth and proliferation among other functions. The pathway begins with a
membrane bound receptor that usually binds an endocrine hormone. The receptor is bound to a
transmembrane protein that, once activated, stimulates a stimulatory or inhibitory trimeric Gprotein, a guanine nucleotide-binding protein that acts as a switch inside cells to transmit signals
that are received outside of the cell. The G-protein stimulates adenylate cyclase to cause the
cyclization of ATP to cAMP. cAMP stimulates protein kinase A (PKA), which will convert ATP to
AMP to phosphorylate other proteins. PKA will also phosphorylate the transcription factor cAMP
Responsive Element Binding Protein (CREB). Once CREB is phosphorylated, it is activated and
diffuses inside the nucleus where it interacts with DNA as a transcription factor, causing the
transcription of certain genes.
8-Cl-cAMP and 8-Cl-Adenosine are both under clinical trials for their therapeutic effects in
treating various types of cancer. These trials have met many issues, one of the major problems
is their solubility properties. 8-Cl-cAMP is known to have high water solubility similar to that of
vitamin C, thus the drug is not able to maintain high enough concentrations in the body to illicit a
response before it is excreted. This problem was overcome by increasing the dosage given to
patients which caused toxic side effects. These side effects can be mitigated, however, by what
has been proposed here. Keeping in mind the solubility of 8-Cl-Adenosine and the fact that it is
readily converted to 8-Cl-ATP which can be further converted to 8-Cl-cAMP through human
biological pathways, a dosage of 8-Cl-Adenosine dissolved in human serum albumin could
provide a constant 8-Cl-cAMP concentration in the blood serum for anti-cancer treatment.
Lowering the dosage of 8-Cl-cAMP and adding an IV dosage of 8-Cl-Adenosine would not only
provide patients with the enhanced anti-cancer effects but also give the body a less toxic source
of 8-Cl-cAMP in the form of 8-Cl-Adenosine. While this modification requires additional clinical
research, augmenting 8-Cl-cAMP treatment with 8-Cl-Adenosine can give patients the more
clinical benefits with minimum toxicity.

The Role of cAMP in Signal Transduction

Conclusion
Background
Both 8-Cl-Adenosine and 8-Cl- cAMP have been found to
inhibit proliferation of cancerous cells. 8-Adenosine is
under clinical phase I study at the M.D. Anderson Cancer
Center under Dr. William Wierda for the treatment of
chronic lymphocytic leukemia while 8-Cl-cAMP has
advanced to clinical phase II studies. Within cells, 8-ClAdenosine and 8-Cl-cAMP are inter-convertible and can
serve as pro-drugs for each other. The mechanisms
through which 8-Cl-cAMP demonstrated the antiproliferative effects have been studied and
published. Findings by Simona Lucchi et al, (2) indicate
that 8-Cl-cAMP is more effective in inhibiting cancer cell
growth than the other PKA I-selective analogs. In this
specific investigation, the use of 8-Cl-cAMP was
associated with cell apoptosis, whereas the use of PKA Iselective analogs only inhibited cell growth. During
inhibition of the p-38 MAPK pathway, the pro-apoptotic
effect of 8-Cl-cAMP was prevented. Further studies
suggested that the 8-Cl-cAMP and PKA I-selective
analogs acted through these mechanisms; cell growth
arrest is induced in cells carrying the BRAF-1 oncogene
in the presence of PKA I-selective analogs, and 8-ClcAMP induced apoptosis through the p-38 MAPK
pathway. These findings indicate that 8-Cl-cAMP indeed
produces anti-cancer effects by slowing down cancer cell
growth and inducing apoptosis for cancer cells. Thus 8Cl-Adenosine, as a pro-drug of 8-Cl-cAMP ensures a
sustained concentration of 8-Cl-cAMP in the blood
plasma. The synergistic effect of using 8-Cl-cAMP and 8Cl-Adenosine in multidrug combination therapy for cancer
patients will maximize the clinical efficacy and duration of
the anti-cancer effects.

Summary of Clinical Trials
- The information toxicity and side effects of 8-Cl-cAMP is readily available
•

Patients at high dosages report decreased renal function and greater
accumulation of drug [1]
•
Decreased renal function causes patients to also present with
hypercalcemia and hepatotoxicity
•
The maximum dosage at which this drug can be administered without
affecting renal function has been found to be 0.15 mg/kg/h, 3 days a
week [1,2]
- The cellular pathways effected by 8-Cl-cAMP are under investigation
•

Evidence has suggested the drug operates through p38 MAPK activation
inducing apoptosis via extrinsic pathways [3]
•
These effects have already been paired synergistically with existing
chemotherapies, including Paclitaxel [4]
- Conversion of 8-Cl-Adenosine to 8-Cl-cAMP has been observed [5]
•

This ability to be interconverted illustrates that the effects of 8-Cl-cAMP
can be supplemented with the less toxic prodrug, 8-Cl-Adenosine

Patient Selection Criteria & Treatment
•
•
•
•

Diagnosis of lymphocytic leukemia
Rai Stage III or IV & 18 years or older
Zubrod performance status less than or equal to 2
Dosage of the Intravenous Treatment:
o 8-Chloro-Adenosine = 45mg/m2/hr
o 8-Chloro-cAMP = 0.15 mg/kg/hr
o One hour per treatment, 3 times/week for 4 weeks

Based on the evidence provided from 8-Cl-cAMP clinical trials, it is clear that this
drug is a powerful tool that can be used to treat various types of cancer. This
benefit comes at a price, however. The drug’s solubility means that plasma
concentrations are harder to control. This is normally corrected by increasing the
drug’s concentration, resulting in toxic side effects. This was seen in the clinical
trials which brought about a decrease in research on this drug; many felt that the
side effects were too costly for patients. However, adding the prodrug 8-ClAdenosine may be able to minimize the side effects while maximizing the
therapeutic effects. This is due to the convertibility of 8-Cl-Adenosine to 8-ClcAMP. Adding 8-Cl-Adenosine would allow for the lowering of the 8-Cl-cAMP
dosage as the body will produce this product as it converts 8-Cl-Adenosine. This
also alleviates the need for time delayed delivery systems. This conversion takes
time, meaning that the body will produce 8-Cl-cAMP at a constant rate, leveling
the plasma concentration over longer periods of time. The combination of the
conversion properties and the time it takes for the conversion to complete
indicate that a combination of 8-Cl-cAMP and 8-Cl-Adenosine would provide the
maximal therapeutic benefits with minimal side effects. These two drugs are thus
prime targets for a combined clinical trial.
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